Clinical Observation on Metastatic or Recurrent Esophageal Cancer Treated with Combination of Docetaxel and Radiotherapy

陈俊强,陈明强,朱坤寿,李云英,潘建基,陈文娟,邱素芳,邵凌东,吴君心

DOI: https://doi.org/10.3969/j.issn.1673-5269.2008.14.014

2008-01-01

Abstract:OBJECTIVE: To evaluate the response and the toxic reaction of metastatic or recurrent esophageal cancer treated with the conbination of docetaxel and radiotherapy. METHODS: The patients with metastatic or recurrent esophageal cancer were treated with 75 mg/m2 of docetaxel d1 and 80 mg/m2 of cisplatin divided in d1, 2, 3, every 21 days, 105 courses to total, 2.5 courses average to per pts. Two days after the chemotherapy, radiotherapy (micro-field to aim directly at Mets,the mean dose was DT 60 Gy/30 F,6 weeks to total) was combined. RESULTS: Forty-two patients were enrolled in this study. The overall response rate was 78.6% with complete response 11(26.2%), partial response 22(52.4%),stable disease 6(14.3%) and progress dissease 3(7.1%). Median TTP was 7.3 months. Median overall survival time was 14.8 months, and the 0.5-, l-year overall survival rate was 89.6% and 67.1%, respectively. The main toxic reaction to confined doses included gradeⅡ/Ⅲleucopenia (42.9%) and tracheitis (36.1%). CONCLUSIONS: The toxic reaction of metastatic or recurrent esophageal cancer treated with the combination of docetaxel and radiotherapy is mild and tolerable, and the recent response is reliable. It is worthy of further clinical research.